Shingles vaccine linked to fewer heart complications in people with heart disease

A large observational study of more than 246,000 U.S. adults with established atherosclerotic cardiovascular disease found that receiving at least one shingles vaccine dose (Shingrix or Zostavax) was associated with substantially lower risks of major cardiovascular events within a year, including a 46% drop in major adverse cardiovascular events, 27% fewer heart attacks, 27% fewer strokes, 33% fewer heart failures, and a 61% reduction in death from any cause, compared with unvaccinated peers. The researchers caution that causality cannot be proven from observational data and longer follow-up is needed, but the findings add to evidence that the shingles vaccine may offer broader health benefits and support vaccination guidelines for adults 50 and older, especially those with cardiovascular disease.